Quantum BioPharma Submits IND for Lucid-MS Trial
TORONTO, April 1, 2026 Quantum BioPharma Ltd. announced the submission of an Investigational New Drug (IND) application to the...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
TORONTO, April 1, 2026 Quantum BioPharma Ltd. announced the submission of an Investigational New Drug (IND) application to the...
NEW YORK, April 3, 2026 MiNK Therapeutics announced that new Phase II clinical trial data for its investigational iNKT...
Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
POTOMAC, Md., Feb. 9, 2026 — IGC Pharma, Inc. announced the expansion of its ongoing Phase 2 CALMA clinical...
SAN FRANCISCO, Calif., Feb. 4, 2026 — Axon Neuroscience announced that its active tau immunotherapy AADvac1 has been selected...
BOULDER, Colorado | December 24, 2025 — Edgewise Therapeutics announced the completion of Parts B and C of the...
Dateline — Encinitas, California, November 8, 2024:Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its third-quarter 2024 results alongside significant progress...
